Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Selection of extraction medium influences cytotoxicity of zinc and its alloys.

Li P, Schille C, Schweizer E, Kimmerle-Müller E, Rupp F, Heiss A, Legner C, Klotz UE, Geis-Gerstorfer J, Scheideler L.

Acta Biomater. 2019 Mar 9. pii: S1742-7061(19)30179-5. doi: 10.1016/j.actbio.2019.03.013. [Epub ahead of print]

PMID:
30862550
2.

Mechanical Characteristics, In Vitro Degradation, Cytotoxicity, and Antibacterial Evaluation of Zn-4.0Ag Alloy as a Biodegradable Material.

Li P, Schille C, Schweizer E, Rupp F, Heiss A, Legner C, Klotz UE, Geis-Gerstorfer J, Scheideler L.

Int J Mol Sci. 2018 Mar 7;19(3). pii: E755. doi: 10.3390/ijms19030755.

3.

Data integration for identification of important transcription factors of STAT6-mediated cell fate decisions.

Jargosch M, Kröger S, Gralinska E, Klotz U, Fang Z, Chen W, Leser U, Selbig J, Groth D, Baumgrass R.

Genet Mol Res. 2016 Jun 24;15(2). doi: 10.4238/gmr.15028493.

4.

Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.

Klotz U, Schmidt D, Willinger B, Steinmann E, Buer J, Rath PM, Steinmann J.

Mycoses. 2016 May;59(5):312-8. doi: 10.1111/myc.12472. Epub 2016 Jan 25.

PMID:
26806376
5.

Paracetamol (acetaminophen) - a popular and widely used nonopioid analgesic.

Klotz U.

Arzneimittelforschung. 2012 Aug;62(8):355-9. doi: 10.1055/s-0032-1321785. Epub 2012 Aug 1. Review.

PMID:
22855300
6.

The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).

Klotz U.

Arzneimittelforschung. 2012 Feb;62(2):53-8. doi: 10.1055/s-0031-1299685. Epub 2012 Feb 16. Review.

PMID:
22344548
7.

Drug interactions with herbal medicines.

Shi S, Klotz U.

Clin Pharmacokinet. 2012 Feb 1;51(2):77-104. doi: 10.2165/11597910-000000000-00000. Review.

PMID:
22257149
8.

Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA.

Dong M, Philippi C, Loretz B, Nafee N, Schaefer UF, Friedel G, Ammon-Treiber S, Griese EU, Lehr CM, Klotz U, Mürdter TE.

Int J Pharm. 2011 Oct 31;419(1-2):33-42. doi: 10.1016/j.ijpharm.2011.07.009. Epub 2011 Jul 18.

PMID:
21782910
9.

Age-related changes in pharmacokinetics.

Shi S, Klotz U.

Curr Drug Metab. 2011 Sep;12(7):601-10. Review.

PMID:
21495970
10.

Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.

König J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF.

Drug Metab Dispos. 2011 Jun;39(6):1097-102. doi: 10.1124/dmd.110.034991. Epub 2011 Mar 23.

PMID:
21430235
11.

Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine.

Dong M, Mürdter TE, Klotz U.

Eur J Clin Pharmacol. 2010 Jan;66(1):1-3. doi: 10.1007/s00228-009-0758-9. Epub 2009 Nov 21. No abstract available.

PMID:
19936723
12.

Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells.

Beisner J, Dong M, Taetz S, Nafee N, Griese EU, Schaefer U, Lehr CM, Klotz U, Mürdter TE.

Lung Cancer. 2010 Jun;68(3):346-54. doi: 10.1016/j.lungcan.2009.07.010. Epub 2009 Aug 19.

PMID:
19695733
13.

Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.

Klotz U.

Arzneimittelforschung. 2009;59(6):271-82. doi: 10.1055/s-0031-1296397. Review.

PMID:
19634508
14.

Pharmacokinetics and drug metabolism in the elderly.

Klotz U.

Drug Metab Rev. 2009;41(2):67-76. doi: 10.1080/03602530902722679. Review.

PMID:
19514965
15.

Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).

Klotz U.

Eur J Clin Pharmacol. 2009 Jan;65(1):1-2. doi: 10.1007/s00228-008-0571-x. Epub 2008 Oct 29. No abstract available.

PMID:
18958459
16.

Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J.

Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. Review.

PMID:
18925391
17.

Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA.

Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer U, Lehr CM, Klotz U, Mürdter TE.

J Pharm Sci. 2009 May;98(5):1765-74. doi: 10.1002/jps.21553.

PMID:
18803262
18.

The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells.

Taetz S, Nafee N, Beisner J, Piotrowska K, Baldes C, Mürdter TE, Huwer H, Schneider M, Schaefer UF, Klotz U, Lehr CM.

Eur J Pharm Biopharm. 2009 Jun;72(2):358-69. doi: 10.1016/j.ejpb.2008.07.011. Epub 2008 Jul 27.

PMID:
18703137
19.

Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Shi S, Klotz U.

Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. doi: 10.1007/s00228-008-0538-y. Epub 2008 Aug 5. Review.

PMID:
18679668
20.

Variability in response to cardiovascular drugs.

El Desoky ES, Derendorf H, Klotz U.

Curr Clin Pharmacol. 2006 Jan;1(1):35-46. Review.

PMID:
18666376
21.

The clinical impact of pharmacogenetics on the treatment of epilepsy.

Löscher W, Klotz U, Zimprich F, Schmidt D.

Epilepsia. 2009 Jan;50(1):1-23. doi: 10.1111/j.1528-1167.2008.01716.x. Epub 2008 Jul 8. Review.

22.

Screening of telomerase inhibitors.

Kleideiter E, Piotrowska K, Klotz U.

Methods Mol Biol. 2007;405:167-80. doi: 10.1007/978-1-60327-070-0_13.

PMID:
18369824
23.

Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential.

Taetz S, Mürdter TE, Zapp J, Boettcher S, Baldes C, Kleideiter E, Piotrowska K, Schaefer UF, Klotz U, Lehr CM.

Int J Pharm. 2008 Jun 5;357(1-2):6-14. doi: 10.1016/j.ijpharm.2008.01.026. Epub 2008 Jan 20.

PMID:
18313869
24.

The clinical implications of ageing for rational drug therapy.

Shi S, Mörike K, Klotz U.

Eur J Clin Pharmacol. 2008 Feb;64(2):183-99. doi: 10.1007/s00228-007-0422-1. Epub 2008 Jan 5. Review.

PMID:
18180915
25.

Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.

Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher DM.

Nephrol Dial Transplant. 2008 Apr;23(4):1241-5. doi: 10.1093/ndt/gfm785. Epub 2008 Jan 3.

PMID:
18174269
26.

The elderly--a challenge for appropriate drug treatment.

Klotz U.

Eur J Clin Pharmacol. 2008 Mar;64(3):225-6. No abstract available.

PMID:
18071682
27.

Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Klotz U.

Clin Pharmacokinet. 2007;46(12):985-96. Review.

PMID:
18027986
28.

Clinical use and pharmacological properties of selective COX-2 inhibitors.

Shi S, Klotz U.

Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. Epub 2007 Nov 13. Review.

PMID:
17999057
29.

Drug-related risks.

Klotz U.

Eur J Clin Pharmacol. 2007 Nov;63(11):983-4. No abstract available.

PMID:
17882407
30.

Clinical pharmacokinetics and use of infliximab.

Klotz U, Teml A, Schwab M.

Clin Pharmacokinet. 2007;46(8):645-60. Review.

PMID:
17655372
31.

The bridging function of clinical pharmacology.

Klotz U.

Eur J Clin Pharmacol. 2007 Sep;63(9):817-9. No abstract available.

PMID:
17634934
32.

Unchanged serum levels of advanced glycation endproducts in patients with liver disease.

Butscheid M, Schäfer C, Brenner S, Alscher D, Mürdter T, Niwa T, Frischmann M, Pischetsrieder M, Klotz U.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Aug;375(6):401-6. Epub 2007 Jun 15.

PMID:
17571253
33.
34.

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M.

Clin Pharmacokinet. 2007;46(3):187-208. Review.

PMID:
17328579
35.

Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.

Treiber G, Malfertheiner P, Klotz U.

Expert Opin Pharmacother. 2007 Feb;8(3):329-50. Review.

PMID:
17266468
36.
37.
38.

Transport studies with 5-aminosalicylate.

Xin HW, Schwab M, Klotz U.

Eur J Clin Pharmacol. 2006 Oct;62(10):871-5. Epub 2006 Aug 30.

PMID:
16944117
39.

Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease.

Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher DM.

J Clin Pathol. 2007 Apr;60(4):415-8. Epub 2006 Jun 14.

40.

Biopharmaceutical characterization of the telomerase inhibitor BRACO19.

Taetz S, Baldes C, Mürdter TE, Kleideiter E, Piotrowska K, Bock U, Haltner-Ukomadu E, Mueller J, Huwer H, Schaefer UF, Klotz U, Lehr CM.

Pharm Res. 2006 May;23(5):1031-7. Epub 2006 May 4.

PMID:
16715394
41.

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.

Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G.

Clin Pharmacol Ther. 2005 Dec;78(6):627-34.

PMID:
16338278
42.

Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.

Hofmann U, Schwab M, Treiber G, Klotz U.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):85-90. Epub 2005 Dec 9.

PMID:
16338182
43.

Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.

Piotrowska K, Kleideiter E, Mürdter TE, Taetz S, Baldes C, Schaefer U, Lehr CM, Klotz U.

Lab Invest. 2005 Dec;85(12):1565-9.

44.

Determinants of non-response in Helicobacter pylori eradication trials.

Klotz U, Treiber G, Schwab M.

J Gastroenterol Hepatol. 2005 Sep;20(9):1471. No abstract available.

PMID:
16105147
45.

Thiopurine S-methyltransferase as a target for drug interactions.

Xin HW, Fischer C, Schwab M, Klotz U.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):395-8. Epub 2005 Jun 11.

PMID:
15952020
46.

[Pharmacology of proton pump inhibitors].

Klotz U.

Pharm Unserer Zeit. 2005;34(3):200-4. Review. German. No abstract available.

PMID:
15940952
47.

Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.

Klotz U.

Dig Liver Dis. 2005 Jun;37(6):381-8. Epub 2005 Mar 2. Review.

PMID:
15893274
48.
49.

Reassessment of the benefit/risk-ratio of selective COX-2-inhibitors.

Klotz U.

Swiss Med Wkly. 2005 Mar 19;135(11-12):166-8. No abstract available.

PMID:
15846528
50.

Distribution of diazepam between plasma and whole blood.

Klotz U.

Ther Drug Monit. 2004 Dec;26(6):693. No abstract available.

PMID:
15570197

Supplemental Content

Support Center